RU2005102836A - Терапевтические комбинации ингибиторов erbb-киназ и противоопухолевые способы лечения - Google Patents
Терапевтические комбинации ингибиторов erbb-киназ и противоопухолевые способы лечения Download PDFInfo
- Publication number
- RU2005102836A RU2005102836A RU2005102836/14A RU2005102836A RU2005102836A RU 2005102836 A RU2005102836 A RU 2005102836A RU 2005102836/14 A RU2005102836/14 A RU 2005102836/14A RU 2005102836 A RU2005102836 A RU 2005102836A RU 2005102836 A RU2005102836 A RU 2005102836A
- Authority
- RU
- Russia
- Prior art keywords
- cancer
- antitumor agent
- tyrosine kinase
- inhibitor
- administering
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 15
- 239000003112 inhibitor Substances 0.000 title claims 5
- 230000001225 therapeutic effect Effects 0.000 title claims 2
- 102000001301 EGF receptor Human genes 0.000 title 1
- 101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 title 1
- 230000000259 anti-tumor effect Effects 0.000 title 1
- 239000002246 antineoplastic agent Substances 0.000 claims 9
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 229940121935 ErbB tyrosine kinase inhibitor Drugs 0.000 claims 3
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 3
- 229930012538 Paclitaxel Natural products 0.000 claims 3
- OMZCMEYTWSXEPZ-UHFFFAOYSA-N canertinib Chemical group C1=C(Cl)C(F)=CC=C1NC1=NC=NC2=CC(OCCCN3CCOCC3)=C(NC(=O)C=C)C=C12 OMZCMEYTWSXEPZ-UHFFFAOYSA-N 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 3
- 229960005277 gemcitabine Drugs 0.000 claims 3
- 230000005865 ionizing radiation Effects 0.000 claims 3
- 229960001592 paclitaxel Drugs 0.000 claims 3
- 230000002062 proliferating effect Effects 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 3
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims 2
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims 2
- 229940009456 adriamycin Drugs 0.000 claims 2
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 229950002826 canertinib Drugs 0.000 claims 2
- 229960004117 capecitabine Drugs 0.000 claims 2
- 229960004562 carboplatin Drugs 0.000 claims 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 2
- 229960004316 cisplatin Drugs 0.000 claims 2
- 229960003668 docetaxel Drugs 0.000 claims 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 2
- 229960005420 etoposide Drugs 0.000 claims 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 2
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims 2
- 229960000303 topotecan Drugs 0.000 claims 2
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 2
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 229940123237 Taxane Drugs 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 238000002648 combination therapy Methods 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 230000003463 hyperproliferative effect Effects 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims 1
- 229940063683 taxotere Drugs 0.000 claims 1
- 238000011285 therapeutic regimen Methods 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40170502P | 2002-08-07 | 2002-08-07 | |
| US60/401,705 | 2002-08-07 | ||
| US46224703P | 2003-04-11 | 2003-04-11 | |
| US60/462,247 | 2003-04-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2005102836A true RU2005102836A (ru) | 2005-08-10 |
Family
ID=31720553
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2005102836/14A RU2005102836A (ru) | 2002-08-07 | 2003-07-28 | Терапевтические комбинации ингибиторов erbb-киназ и противоопухолевые способы лечения |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20040067942A1 (enExample) |
| EP (1) | EP1549320A1 (enExample) |
| JP (1) | JP2005538129A (enExample) |
| CN (1) | CN1674908A (enExample) |
| AR (1) | AR040792A1 (enExample) |
| AU (1) | AU2003249450A1 (enExample) |
| BR (1) | BR0313470A (enExample) |
| CA (1) | CA2494270A1 (enExample) |
| IL (1) | IL166423A0 (enExample) |
| MX (1) | MXPA05001430A (enExample) |
| NO (1) | NO20051170L (enExample) |
| PA (1) | PA8578001A1 (enExample) |
| PE (1) | PE20040990A1 (enExample) |
| PL (1) | PL375414A1 (enExample) |
| RU (1) | RU2005102836A (enExample) |
| TW (1) | TW200404532A (enExample) |
| WO (1) | WO2004014386A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2325199C2 (ru) * | 2006-06-20 | 2008-05-27 | Государственное учреждение научно-исследовательский институт онкологии Томского Научного центра Сибирского отделения Российской академии медицинских наук (ГУ НИИ онкологии ТНЦ СО РАМН) | Способ комбинированного лечения местно-распространенных форм рака шейки матки |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7951780B2 (en) * | 2004-02-25 | 2011-05-31 | Astellas Pharma Inc. | Antitumor agent |
| US7695731B2 (en) * | 2004-03-22 | 2010-04-13 | Cordis Corporation | Local vascular delivery of etoposide in combination with rapamycin to prevent restenosis following vascular injury |
| US7910593B2 (en) | 2004-04-09 | 2011-03-22 | Chugai Seiyaku Kabushiki Kaisha | Water-soluble prodrugs |
| HRP20110958T1 (hr) | 2004-05-06 | 2012-01-31 | Warner-Lambert Company Llc | 4-fenilaminokinazolin-6-ilamidi |
| WO2005117916A1 (en) | 2004-06-03 | 2005-12-15 | F. Hoffmann-La Roche Ag | Treatment with cisplatin and an egfr-inhibitor |
| JP2008501652A (ja) * | 2004-06-03 | 2008-01-24 | エフ．ホフマン−ラ ロシュ アーゲー | ゲムシタビン及びｅｇｆｒインヒビターによる治療 |
| RU2006146625A (ru) * | 2004-06-03 | 2008-07-20 | Ф.Хоффманн-Ля Рош Аг (Ch) | Лечение иринотеканом (срт-11) и ингибитором рецептора эпидермального фактора роста (egfr) |
| MXPA06013952A (es) * | 2004-06-04 | 2007-02-08 | Smithkline Beecham Cork Ltd | Metodo para el tratamiento de cancer. |
| TW200744603A (en) | 2005-08-22 | 2007-12-16 | Chugai Pharmaceutical Co Ltd | Novel anticancer concomitant drug |
| US20080045589A1 (en) * | 2006-05-26 | 2008-02-21 | Susan Kelley | Drug Combinations with Substituted Diaryl Ureas for the Treatment of Cancer |
| US8168661B2 (en) | 2006-11-06 | 2012-05-01 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US8173686B2 (en) | 2006-11-06 | 2012-05-08 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US8168662B1 (en) | 2006-11-06 | 2012-05-01 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US8178564B2 (en) | 2006-11-06 | 2012-05-15 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| AR064106A1 (es) * | 2006-12-05 | 2009-03-11 | Bayer Schering Pharma Ag | Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis |
| WO2009064738A2 (en) * | 2007-11-12 | 2009-05-22 | Bipar Sciences, Inc. | Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents |
| CN103596592A (zh) * | 2011-05-06 | 2014-02-19 | 梅里麦克制药股份有限公司 | 用于预防包含抗ErbB3试剂的联合治疗中的毒性药物间相互作用的方法 |
| US20210275518A1 (en) * | 2020-03-06 | 2021-09-09 | Deciphera Pharmaceuticals, Llc | Methods of using rebastinib in the treatment of disorders |
| CN118576599A (zh) * | 2020-10-23 | 2024-09-03 | 和记黄埔医药（上海）有限公司 | 一种药物组合产品在制备用于治疗非小细胞肺癌的药物中的用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6287223B1 (en) * | 1997-04-11 | 2001-09-11 | Liechty, Ii Victor Jay | Dulling prevention for sharp cutting edge of blade-opening arrowhead blades when in a closed in-flight position |
| US6147107A (en) * | 1998-12-20 | 2000-11-14 | Virginia Commonwealth University | Specific inhibition of the P42/44 mitogen activated protein (map) kinase cascade sensitizes tumor cells |
| US6281223B1 (en) * | 1999-04-13 | 2001-08-28 | Supergen, Inc. | Radioenhanced camptothecin derivative cancer treatments |
| CA2436326C (en) * | 2001-01-09 | 2012-08-14 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors |
-
2003
- 2003-07-22 PA PA20038578001A patent/PA8578001A1/es unknown
- 2003-07-28 CN CNA038191180A patent/CN1674908A/zh active Pending
- 2003-07-28 WO PCT/IB2003/003388 patent/WO2004014386A1/en not_active Ceased
- 2003-07-28 EP EP03784371A patent/EP1549320A1/en not_active Withdrawn
- 2003-07-28 CA CA002494270A patent/CA2494270A1/en not_active Abandoned
- 2003-07-28 MX MXPA05001430A patent/MXPA05001430A/es unknown
- 2003-07-28 AU AU2003249450A patent/AU2003249450A1/en not_active Abandoned
- 2003-07-28 IL IL16642303A patent/IL166423A0/xx unknown
- 2003-07-28 PL PL03375414A patent/PL375414A1/xx not_active Application Discontinuation
- 2003-07-28 BR BR0313470-9A patent/BR0313470A/pt not_active IP Right Cessation
- 2003-07-28 RU RU2005102836/14A patent/RU2005102836A/ru not_active Application Discontinuation
- 2003-07-28 JP JP2004527183A patent/JP2005538129A/ja not_active Withdrawn
- 2003-08-01 US US10/632,281 patent/US20040067942A1/en not_active Abandoned
- 2003-08-04 PE PE2003000768A patent/PE20040990A1/es not_active Application Discontinuation
- 2003-08-05 AR AR20030102806A patent/AR040792A1/es unknown
- 2003-08-06 TW TW092121515A patent/TW200404532A/zh unknown
-
2005
- 2005-03-04 NO NO20051170A patent/NO20051170L/no unknown
-
2006
- 2006-08-14 US US11/464,249 patent/US20060293323A1/en not_active Abandoned
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2325199C2 (ru) * | 2006-06-20 | 2008-05-27 | Государственное учреждение научно-исследовательский институт онкологии Томского Научного центра Сибирского отделения Российской академии медицинских наук (ГУ НИИ онкологии ТНЦ СО РАМН) | Способ комбинированного лечения местно-распространенных форм рака шейки матки |
Also Published As
| Publication number | Publication date |
|---|---|
| US20060293323A1 (en) | 2006-12-28 |
| US20040067942A1 (en) | 2004-04-08 |
| NO20051170L (no) | 2005-05-06 |
| IL166423A0 (en) | 2006-01-15 |
| MXPA05001430A (es) | 2005-06-06 |
| PE20040990A1 (es) | 2004-12-27 |
| EP1549320A1 (en) | 2005-07-06 |
| WO2004014386A1 (en) | 2004-02-19 |
| CA2494270A1 (en) | 2004-02-19 |
| AU2003249450A1 (en) | 2004-02-25 |
| JP2005538129A (ja) | 2005-12-15 |
| TW200404532A (en) | 2004-04-01 |
| PA8578001A1 (es) | 2004-05-07 |
| PL375414A1 (en) | 2005-11-28 |
| CN1674908A (zh) | 2005-09-28 |
| BR0313470A (pt) | 2005-06-21 |
| AR040792A1 (es) | 2005-04-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Haider et al. | An appraisal of anticancer activity with structure–activity relationship of quinazoline and quinazolinone analogues through EGFR and VEGFR inhibition: A review | |
| WO2007106503A3 (en) | Combined treatment with an egfr kinase inhibitor and an agent that sensitizes tumor cells to the effects of egfr kinase inhibitors | |
| Choy | Taxanes in combined modality therapy for solid tumors | |
| RU2011119638A (ru) | Способ лечения | |
| RU2013131004A (ru) | Комбинация (а) ингибитора фосфоинозит-3-киназы и (б) модулятора пути ras/raf/mek | |
| JP2010516770A5 (enExample) | ||
| PE20070207A1 (es) | Tratamiento combinado de los tumores que expresan el her | |
| RU2009132674A (ru) | Комбинированная терапия с использованием ингибиторов ангиогенеза | |
| RU2007126978A (ru) | Комбинации терапевтических агентов для лечения рака | |
| CN105120663B (zh) | 用于利用羧胺三唑乳清酸盐治疗对先前化学治疗药物和靶向药物具有获得性耐药性的癌症的方法和组合物 | |
| MX2007004549A (es) | Tratamiento combinado con bortezomib y un inhibidor de cinasa del receptor del factor de crecimiento epidermico. | |
| RU2007141654A (ru) | Противоопухолевая комбинированная терапия, в которой используется сунитиниб-малат | |
| EA201000127A1 (ru) | Специфическая терапия и лекарственное средство на основе интегриновых лигандов для лечения рака | |
| JP2006500346A (ja) | 癌の処置のためのｖｅｇｆ受容体チロシンキナーゼ阻害剤の組み合わせ | |
| JP2005538129A5 (enExample) | ||
| RU2017105817A (ru) | Комбинированная терапия | |
| WO2006110176A3 (en) | Combined treatment with radiation and an epidermal growth factor receptor kinase inhibitor | |
| Reibenwein et al. | Targeting signaling pathways in ovarian cancer | |
| TW200603804A (en) | Treatment with irinotecan (cpt-11) and an EGFR-inhibitor | |
| RU2019134769A (ru) | Композиции для лечения резистентных к лекарственным средствам опухолей и способы их применения | |
| JP2011500723A5 (enExample) | ||
| RU2010119922A (ru) | Усовершенствованное противоопухолевое лечение | |
| WO2009073139A3 (en) | Combined treatment with an egfr kinase inhibitor and an inhibitor of c-kit | |
| Blackledge et al. | Anti-EGF receptor therapy | |
| MX2024014940A (es) | Terapia combinada para el tratamiento del cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20070316 |